Publikationer

This page in English

Dietary micronutrient intake and atherosclerosis in systemic lupus erythematosus.
Lourdudoss C, Elkan A, Hafström I, Jogestrand T, Gustafsson T, van Vollenhoven R, et al
Lupus 2016 Dec;25(14):1602-1609

Prevalence and comorbidity of relapsing polychondritis.
Ludvigsson J, van Vollenhoven R
Clin Epidemiol 2016 ;8():361-362

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
Emamikia S, Arkema E, Györi N, Detert J, Chatzidionysiou K, Dougados M, et al
RMD Open 2016 ;2(2):e000323

Off-label use of rituximab for systemic lupus erythematosus in Europe.
Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio J, Caminal-Montero L, Castro A, et al
Lupus Sci Med 2016 ;3(1):e000163

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
Levitsky A, Wick M, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, et al
Clin. Exp. Rheumatol. ;34(6):1065-1071

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Emery P, Bingham C, Burmester G, Bykerk V, Furst D, Mariette X, et al
Ann. Rheum. Dis. 2016 Oct;75(10):e69

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
Fleischmann R, Huizinga T, Kavanaugh A, Wilkinson B, Kwok K, DeMasi R, et al
RMD Open 2016 ;2(2):e000262

Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists.
Lesuis N, den Broeder A, van Vollenhoven R, Vriezekolk J, Hulscher M
Scand. J. Rheumatol. 2016 Jul;():1-6

Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.
Lesuis N, Verhoef L, Nieboer L, Bruyn G, Baudoin P, van Vollenhoven R, et al
Scand. J. Rheumatol. 2016 Jul;():1-4

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
Quattrocchi E, Østergaard M, Taylor P, van Vollenhoven R, Chu M, Mallett S, et al
PLoS ONE 2016 ;11(6):e0157961

Dietary micronutrient intake and atherosclerosis in systemic lupus erythematosus.
Lourdudoss C, Elkan A, Hafström I, Jogestrand T, Gustafsson T, van Vollenhoven R, et al
Lupus 2016 Dec;25(14):1602-1609

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Genovese M, van Vollenhoven R, Wilkinson B, Wang L, Zwillich S, Gruben D, et al
Arthritis Res. Ther. 2016 Jun;18():145

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.
van Vollenhoven R
Ann. Rheum. Dis. 2016 Nov;75(11):1899-1901

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, et al
Arthritis Res. Ther. 2016 Jun;18(1):144

Systemic lupus erythematosus.
Kaul A, Gordon C, Crow M, Touma Z, Urowitz M, van Vollenhoven R, et al
Nat Rev Dis Primers 2016 Jun;2():16039

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky D, Naredo E, et al
Ann. Rheum. Dis. 2016 Aug;75(8):1428-37

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, et al
RMD Open 2016 ;2(1):e000213

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.
Lesuis N, den Broeder A, Hulscher M, van Vollenhoven R
RMD Open 2016 ;2(1):e000195

New therapeutic approaches in rheumatoid arthritis.
van Vollenhoven R
Presse Med 2016 Jun;45(6 Pt 2):e179-92

Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens J, Fautrel B, et al
Ann. Rheum. Dis. 2017 Jan;76(1):126-132

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P, Bingham C, Burmester G, Bykerk V, Furst D, Mariette X, et al
Ann. Rheum. Dis. 2017 Jan;76(1):96-104

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K, Dreyer L, Arkema E, Glintborg B, Jacobsson L, Kristensen L, et al
Ann. Rheum. Dis. 2017 Jan;76(1):105-111

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.
Rovin B, van Vollenhoven R, Aranow C, Wagner C, Gordon R, Zhuang Y, et al
2016 Sep;68(9):2174-83

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.
Urowitz M, Gladman D, Anderson N, Su J, Romero-Diaz J, Bae S, et al
Lupus Sci Med 2016 ;3(1):e000143

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, et al
Lupus 2016 Nov;25(13):1420-1430

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.
Smolen J, Collaud Basset S, Boers M, Breedveld F, Edwards C, Kvien T, et al
Ann. Rheum. Dis. 2016 Jul;75(7):1268-71

Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.
Eriksson J, Wallman J, Miller H, Petersson I, Ernestam S, Vivar N, et al
Arthritis Care Res (Hoboken) 2016 Dec;68(12):1758-1766

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
van Vollenhoven R, Petri M, Wallace D, Roth D, Molta C, Hammer A, et al
2016 Sep;68(9):2184-92

A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.
Hanly J, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae S, et al
2016 Aug;68(8):1932-44

Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis.
Ljung L, Rantapää-Dahlqvist S, Jacobsson L, Askling J
Ann. Rheum. Dis. 2016 Dec;75(12):2087-2094

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
Hambardzumyan K, Bolce R, Saevarsdottir S, Forslind K, Wallman J, Cruickshank S, et al
RMD Open 2016 ;2(1):e000197

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce I, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al
Lupus 2016 Jun;25(7):699-709

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Strand V, van Vollenhoven R, Lee E, Fleischmann R, Zwillich S, Gruben D, et al
Rheumatology (Oxford) 2016 Jun;55(6):1031-41

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, et al
Arthritis Res. Ther. 2016 Feb;18():50

The association between diet and glucocorticoid treatment in patients with SLE.
Lourdudoss C, Hafström I, Frostegård J, van Vollenhoven R
Lupus Sci Med 2016 ;3(1):e000135

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, et al
RMD Open 2016 ;2(1):e000133

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
Kievit W, van Herwaarden N, van den Hoogen F, van Vollenhoven R, Bijlsma J, van den Bemt B, et al
Ann. Rheum. Dis. 2016 Nov;75(11):1939-1944

Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment.
van Vollenhoven R
Nat Rev Rheumatol 2016 Mar;12(3):135-6

Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
Wadström H, Frisell T, Sparén P, Askling J,
Ann. Rheum. Dis. 2016 Jul;75(7):1272-8

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese M, van Vollenhoven R, Pacheco-Tena C, Zhang Y, Kinnman N
2016 Jan;68(1):46-55

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.
Stoffer M, Schoels M, Smolen J, Aletaha D, Breedveld F, Burmester G, et al
Ann. Rheum. Dis. 2016 Jan;75(1):16-22

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.
Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P, et al
Ann. Rheum. Dis. 2016 Jan;75(1):3-15

The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Hanly J, O'Keeffe A, Su L, Urowitz M, Romero-Diaz J, Gordon C, et al
Rheumatology (Oxford) 2016 Feb;55(2):252-62

Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker U, Jaeger V, Chatzidionysiou K, Hetland M, Hauge E, Pavelka K, et al
Rheumatology (Oxford) 2016 Feb;55(2):230-6

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
van Vollenhoven R, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, et al
Ann. Rheum. Dis. 2016 Jan;75(1):52-8

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson J, Petersson I, et al
Ann. Rheum. Dis. 2016 Feb;75(2):356-61

Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists.
Lesuis N, Hulscher M, Piek E, Demirel H, van der Laan-Baalbergen N, Meek I, et al
Arthritis Care Res (Hoboken) 2016 Apr;68(4):562-9

Does disease activity at start of biologic therapy influence work-loss in RA patients?
Olofsson T, Johansson K, Eriksson J, van Vollenhoven R, Miller H, Petersson I, et al
Rheumatology (Oxford) 2016 Apr;55(4):729-34

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Merrill J, van Vollenhoven R, Buyon J, Furie R, Stohl W, Morgan-Cox M, et al
Ann. Rheum. Dis. 2016 Feb;75(2):332-40

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
Gabay C, Riek M, Hetland M, Hauge E, Pavelka K, Tomšič M, et al
Ann. Rheum. Dis. 2016 Jul;75(7):1336-42

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Burmester G, Rigby W, van Vollenhoven R, Kay J, Rubbert-Roth A, Kelman A, et al
Ann. Rheum. Dis. 2016 Jun;75(6):1081-91

Reply.
Pope J, Rothfield N, Ramsey-Goldman R, Douglas Smith C, Bernatsky S, Furie R, et al
Arthritis Care Res (Hoboken) 2016 Jul;68(7):1053-4

Reply.
Lesuis N, Piek E, Demirel H, den Broeder A, Hulscher M, Meek I, et al
Arthritis Care Res (Hoboken) 2016 Jul;68(7):1051

2015

Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.
Hanly J, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae S, et al
2015 Jul;67(7):1837-47

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt M, Fleischmann R, van Vollenhoven R, Emery P, Huizinga T, Cutolo M, et al
Arthritis Res. Ther. 2015 Nov;17():325

Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging.
Kisten Y, Györi N, Af Klint E, Rezaei H, Levitsky A, Karlsson A, et al
RMD Open 2015 ;1(1):e000106

Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients.
Kievit W, van Herwaarden N, van den Hoogen F, van Vollenhoven R, Bijlsma H, van den Bemt B, et al
Value Health 2015 Nov;18(7):A647-8

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
Hui-Yuen J, Reddy A, Taylor J, Li X, Eichenfield A, Bermudez L, et al
J. Rheumatol. 2015 Dec;42(12):2288-95

Remission in SLE: closing in on the target.
van Vollenhoven R, Voskuyl A, Morand E, Aranow C
Ann. Rheum. Dis. 2015 Dec;74(12):2103-6

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.
Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, et al
RMD Open 2015 ;1(1):e000044

Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Levitsky A, Erlandsson M, van Vollenhoven R, Bokarewa M
BMC Med 2015 Sep;13():247

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen J, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, et al
Arthritis Res. Ther. 2015 Sep;17():245

Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.
van Herwaarden N, Bouman C, van der Maas A, van Vollenhoven R, Bijlsma J, van den Hoogen F, et al
Ann. Rheum. Dis. 2015 Dec;74(12):2260-1

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
van Vollenhoven R, Fleischmann R, Furst D, Lacey S, Lehane P
J. Rheumatol. 2015 Oct;42(10):1761-6

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Nagy G, van Vollenhoven R
Arthritis Res. Ther. 2015 Aug;17():181

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.
van Vollenhoven R, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson I, et al
2015 Nov;67(11):2855-60

Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
Johansson K, Eriksson J, van Vollenhoven R, Miller H, Askling J, Neovius M, et al
Rheumatology (Oxford) 2015 Aug;54(8):1472-7

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, et al
Ann. Rheum. Dis. 2015 Aug;74(8):1509-14

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K, Askling J, Eriksson J, Kristensen L, van Vollenhoven R,
Ann. Rheum. Dis. 2015 May;74(5):890-6

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Arkema E, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al
Ann. Rheum. Dis. 2015 Jun;74(6):1212-7

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
Parker B, Urowitz M, Gladman D, Lunt M, Donn R, Bae S, et al
Ann. Rheum. Dis. 2015 Aug;74(8):1530-6

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson J, Karlsson J, Bratt J, Petersson I, van Vollenhoven R, Ernestam S, et al
Ann. Rheum. Dis. 2015 Jun;74(6):1094-101

Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven R, Wax S, Li Y, Tak P
2015 Nov;67(11):2828-36

Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K, Kristensen L, Eriksson J, Askling J, van Vollenhoven R,
Scand. J. Rheumatol. 2015 ;44(6):431-7

Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Levitsky A, Forslind K, van Vollenhoven R,
Scand. J. Rheumatol. 2015 ;44(5):348-53

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
Smolen J, Weinblatt M, van der Heijde D, Rigby W, van Vollenhoven R, Bingham C, et al
Ann. Rheum. Dis. 2015 Aug;74(8):1567-70

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
van Herwaarden N, van der Maas A, Minten M, van den Hoogen F, Kievit W, van Vollenhoven R, et al
BMJ 2015 Apr;350():h1389

Treatment Algorithms in Systemic Lupus Erythematosus.
Muangchan C, van Vollenhoven R, Bernatsky S, Smith C, Hudson M, Inanç M, et al
Arthritis Care Res (Hoboken) 2015 Sep;67(9):1237-45

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.
van Vollenhoven R, Layton M, Kahl L, Schifano L, Hachulla E, Machado D, et al
Lupus 2015 May;24(6):648-9

The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E, Kristensen L, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson L, et al
Ann. Rheum. Dis. 2015 Jun;74(6):970-8

Anti-C1q antibodies in systemic lupus erythematosus.
Orbai A, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón G, et al
Lupus 2015 Jan;24(1):42-9

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
Bykerk V, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al
Ann. Rheum. Dis. 2015 Jan;74(1):96-103

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank S, Sasso E, Chernoff D, et al
Ann. Rheum. Dis. 2015 Jun;74(6):1102-9

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Bruce I, O'Keeffe A, Farewell V, Hanly J, Manzi S, Su L, et al
Ann. Rheum. Dis. 2015 Sep;74(9):1706-13

Differences and similarities in rheumatology specialty training programmes across European countries.
Sivera F, Ramiro S, Cikes N, Dougados M, Gossec L, Kvien T, et al
Ann. Rheum. Dis. 2015 Jun;74(6):1183-7

1987-2014

2013-2014

2011-2012

2009-2010

2007-2008

2001-2006

1987-2000

InflammationReumatologi